Report of Foreign Issuer (6-k)
May 23 2019 - 5:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: May 2019
Commission file number: 001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name into
English)
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
Attached hereto and incorporated herein is
the Registrant’s press release issued on
May 23, 2019,
titled “Therapix
Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance.”
This Report of Foreign Private Issuer on Form
6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-225745) and on Form S-8 (File No. 333-225773)
of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Therapix Biosciences Ltd.
|
Date: May 23, 2019
|
|
|
By:
|
/s/ Oz Adler
|
|
|
Name: Oz Adler
Title: Chief Financial Officer
|
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2023 to Apr 2024